Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings.

Maghdoori S, Moghadas SM.

BMC Infect Dis. 2017 Jun 2;17(1):384. doi: 10.1186/s12879-017-2494-6.

2.

Treatment of Recurrent Clostridium difficile Diarrhea.

Huebner ES, Surawicz CM.

Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.

3.

Gastrointestinal Organoids: Understanding the Molecular Basis of the Host-Microbe Interface.

Hill DR, Spence JR.

Cell Mol Gastroenterol Hepatol. 2016 Dec 19;3(2):138-149. doi: 10.1016/j.jcmgh.2016.11.007. eCollection 2017 Mar. Review.

4.

Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance.

Park L, Mone A, Price JC, Tzimas D, Hirsh J, Poles MA, Malter L, Chen LA.

Ann Gastroenterol. 2017;30(1):83-88. doi: 10.20524/aog.2016.0098. Epub 2016 Oct 20.

5.

A multi-center study of fidaxomicin use for Clostridium difficile infection.

Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW.

Springerplus. 2016 Aug 2;5(1):1224. doi: 10.1186/s40064-016-2825-x. eCollection 2016.

6.

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes.

Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, Gorbach SL.

Can J Infect Dis Med Microbiol. 2016;2016:8048757. doi: 10.1155/2016/8048757. Epub 2016 May 24.

7.

Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.

Ross CL, Spinler JK, Savidge TC.

Anaerobe. 2016 Oct;41:37-43. doi: 10.1016/j.anaerobe.2016.05.006. Epub 2016 May 12. Review.

PMID:
27180006
8.

Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

McFarland LV, Ozen M, Dinleyici EC, Goh S.

World J Gastroenterol. 2016 Mar 21;22(11):3078-104. doi: 10.3748/wjg.v22.i11.3078. Review.

9.

Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S.

PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.

10.

Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital.

Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, Totsuka K.

Clin Exp Gastroenterol. 2015 Jul 14;8:191-6. doi: 10.2147/CEG.S85007. eCollection 2015.

11.

C. difficile Infection: Changing Epidemiology and Management Paradigms.

Vindigni SM, Surawicz CM.

Clin Transl Gastroenterol. 2015 Jul 9;6:e99. doi: 10.1038/ctg.2015.24.

12.

Recurrent Clostridium difficile infection: From colonization to cure.

Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP.

Anaerobe. 2015 Aug;34:59-73. doi: 10.1016/j.anaerobe.2015.04.012. Epub 2015 Apr 27. Review.

13.

Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.

Lv Z, Peng G, Liu W, Xu H, Su J.

Antimicrob Agents Chemother. 2015 Jul;59(7):3726-35. doi: 10.1128/AAC.04794-14. Epub 2015 Mar 30.

14.
15.
16.

Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.

Collins CE, Ayturk MD, Anderson FA Jr, Santry HP.

J Gastrointest Surg. 2015 Jan;19(1):88-99; discussion 99. doi: 10.1007/s11605-014-2638-6. Epub 2014 Nov 19.

17.

Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study.

Doh YS, Kim YS, Jung HJ, Park YI, Mo JW, Sung H, Lee KJ, Seo YK, Moon JS, Hong SW.

Intest Res. 2014 Oct;12(4):299-305. doi: 10.5217/ir.2014.12.4.299. Epub 2014 Oct 27.

18.

Novel risk factors for recurrent Clostridium difficile infection in children.

Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM.

J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):18-22. doi: 10.1097/MPG.0000000000000553.

19.

Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection.

Mullish BH, Marchesi JR, Thursz MR, Williams HR.

QJM. 2015 May;108(5):355-9. doi: 10.1093/qjmed/hcu182. Epub 2014 Sep 4. Review.

20.

Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.

Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW.

PLoS One. 2014 Jul 24;9(7):e102848. doi: 10.1371/journal.pone.0102848. eCollection 2014.

Supplemental Content

Support Center